CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo, M.D., Ph.D., of the New York University (NYU) Fertility Center and the Division of Reproductive Endocrinology at the NYU School of Medicine, to its Clinical Advisory Board.
“Throughout his career, Dr. Grifo has been at the forefront of bringing the latest innovations in fertility to patients, such as pre-implantation genetic diagnosis,” said Michelle Dipp, Chief Executive Officer, OvaScience. “His research continues to drive major advances in the field and we look forward to his contributions to OvaScience.”
“As more women delay childbearing, which can result in decreased egg quality, there are a growing number of patients seeking fertility treatments that could benefit from new innovations in the field,” said Dr. Grifo. “OvaScience’s EggPCSM technology is unique in that it has the potential to improve egg quality and offer new possibilities for helping women build their own families.”
Dr. Grifo is renowned in reproductive medicine for his technical innovation and leadership. His team pioneered the first successful use of pre-implantation genetic diagnosis (PGD) in the U.S., a technique which has been used in the assisted reproduction of thousands of children worldwide. Dr. Grifo’s research also produced the NYU Vitrification Method, a standard of care at NYU Fertility Center since 2004. Additional research focuses on egg freezing and stem cells.
Dr. Grifo is the Program Director of the New York University (NYU) Fertility Center. Since 1995 he has been the Director of the Division of Reproductive Endocrinology at the NYU School of Medicine where he also holds the faculty appointment of Professor of Obstetrics and Gynecology. He received his M.D. and Ph.D. degrees at Case Western Reserve School of Medicine. A member of the American Society for Reproductive Medicine since 1989, Dr. Grifo has served on the Ethics Committee and is past president of the Society for Assisted Reproductive Technologies.
OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new fertility treatments. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation in vitro fertilization (IVF) treatments. The Company currently has three fertility treatments in development: AUGMENTSM, which aims to improve egg quality and increase the success of IVF; OvaPrimeSM, designed to boost a woman’s egg reserve using her own EggPCs; and OvaTureSM, which seeks to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections. OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.
This press release includes forward-looking statements about the prospects for the Company’s technology in addressing female infertility, the Company’s strategy, future plans and prospects, and the development and commercialization of the Company’s product candidates. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT outside of the United States and our expectation that AUGMENT meets the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we plan to introduce AUGMENT in ACE clinics; the science underlying our product candidates (including AUGMENT, OvaPrime and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties, including our dependence on Intrexon Corporation; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to develop our product candidates, including AUGMENT, OvaPrime and OvaTure, on the timelines we expect, if at all; our ability to commercialize our product candidates, including AUGMENT and OvaPrime, on the timelines we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.